AU2021255084B2 - Breast cancer therapeutic agent - Google Patents

Breast cancer therapeutic agent

Info

Publication number
AU2021255084B2
AU2021255084B2 AU2021255084A AU2021255084A AU2021255084B2 AU 2021255084 B2 AU2021255084 B2 AU 2021255084B2 AU 2021255084 A AU2021255084 A AU 2021255084A AU 2021255084 A AU2021255084 A AU 2021255084A AU 2021255084 B2 AU2021255084 B2 AU 2021255084B2
Authority
AU
Australia
Prior art keywords
breast cancer
cdk4
estrogen receptor
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021255084A
Other languages
English (en)
Other versions
AU2021255084A1 (en
Inventor
Sayo Fukushima
Satoshi Kawano
Saori Miyano
Kyoko Nishibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2021255084A1 publication Critical patent/AU2021255084A1/en
Application granted granted Critical
Publication of AU2021255084B2 publication Critical patent/AU2021255084B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021255084A 2020-04-17 2021-04-15 Breast cancer therapeutic agent Active AU2021255084B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020074386 2020-04-17
JP2020-074386 2020-04-17
PCT/JP2021/015546 WO2021210636A1 (ja) 2020-04-17 2021-04-15 乳がん治療剤

Publications (2)

Publication Number Publication Date
AU2021255084A1 AU2021255084A1 (en) 2022-12-08
AU2021255084B2 true AU2021255084B2 (en) 2026-04-02

Family

ID=78084563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021255084A Active AU2021255084B2 (en) 2020-04-17 2021-04-15 Breast cancer therapeutic agent

Country Status (10)

Country Link
US (1) US20230149381A1 (https=)
EP (1) EP4122465A4 (https=)
JP (1) JPWO2021210636A1 (https=)
KR (1) KR20230004595A (https=)
CN (1) CN115397415A (https=)
AU (1) AU2021255084B2 (https=)
BR (1) BR112022020786A2 (https=)
CA (1) CA3180128A1 (https=)
MX (1) MX2022012934A (https=)
WO (1) WO2021210636A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
AU2021315234A1 (en) * 2020-07-31 2023-01-19 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017104739A1 (ja) * 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
JP2018022750A (ja) 2016-08-02 2018-02-08 太陽誘電株式会社 積層セラミックコンデンサ
WO2018049233A1 (en) * 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017104739A1 (ja) * 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. WATANABE MIYANO ET AL: "E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models", MOLECULAR CANCER THERAPEUTICS, vol. 15, no. 11 *

Also Published As

Publication number Publication date
MX2022012934A (es) 2022-11-08
EP4122465A1 (en) 2023-01-25
US20230149381A1 (en) 2023-05-18
CA3180128A1 (en) 2021-10-21
BR112022020786A2 (pt) 2022-11-29
KR20230004595A (ko) 2023-01-06
CN115397415A (zh) 2022-11-25
AU2021255084A1 (en) 2022-12-08
JPWO2021210636A1 (https=) 2021-10-21
WO2021210636A1 (ja) 2021-10-21
EP4122465A4 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
AU2021255084B2 (en) Breast cancer therapeutic agent
US9023354B2 (en) Combination therapy with MDM2 and EFGR inhibitors
TW201118082A (en) Combinations of a PI3K inhibitor and a MEK inhibitor
CN103945848A (zh) 被取代的喹唑啉酮的口服即释制剂
TW202541800A (zh) 化合物之調配物及其用途
KR102469406B1 (ko) 재발된 및/또는 난치성 고형 종양 및 비-호지킨 림프종의 치료
CN110198716A (zh) 癌症治疗
TW202342050A (zh) 用於治療進行性纖維化間質性肺病之新穎治療組合
WO2021216814A1 (en) Btk inhibitors to treat pulmonary distress in covid-19 patients
CN112040944A (zh) 用于治疗癌症的组合
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
US11571411B2 (en) Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals
US12186320B2 (en) Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient
MD4802C1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
RU2847580C1 (ru) Терапевтическое средство против рака молочной железы
JP2024505515A5 (https=)
EP4370125A1 (en) Phthalazinone-based parp-1 inhibitors
JP2023538659A (ja) Ｏｌｉｇ２阻害剤を用いる併用療法
WO2021104341A1 (zh) 一种取代丁烯酰胺的应用
CN105683185A (zh) 作为mpges-1抑制剂的新型哌啶基苯并咪唑衍生物
US20200147039A1 (en) Compounds useful in inhibiting human trefoil factor 3
US20240238220A1 (en) Methods for treating cancers
EP4638443A1 (en) Transient receptor potential vanilloid 6 inhibitors
CN121889151A (zh) Wee1抑制剂和pkmyt1抑制剂的组合